BioCentury
ARTICLE | Company News

EC approves AbbVie's HCV regimen

January 17, 2015 4:39 AM UTC

The European Commission approved Exviera dasabuvir and Viekirax, a two direct-acting-antiviral (2-DAA) combination of ombitasvir and paritaprevir plus the booster Norvir ritonavir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV infection.

The EC approved the 3-DAA combination of Viekirax plus Exviera, with or without ribavirin, to treat HCV genotype 1, including patients with compensated cirrhosis or HIV-1 co-infection, those on opioid substitution therapy and liver transplant recipients. The EC also approved Viekirax plus ribavirin to treat HCV genotype 4. ...